These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30500381)

  • 41. Emergency department management of nerve agent exposure.
    Pfaff BL
    Int J Trauma Nurs; 1998; 4(3):71-8. PubMed ID: 9855972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemical Agents in Disaster: Care and Management in the Intensive Care Unit.
    Mishra R; Geiling J
    Crit Care Clin; 2019 Oct; 35(4):633-645. PubMed ID: 31445610
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toxicological aspects of preparedness and aftercare for chemical-incidents.
    Schwenk M; Kluge S; Jaroni H
    Toxicology; 2005 Oct; 214(3):232-48. PubMed ID: 16118031
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How to curb production of chemical weapons.
    Sydnes LK
    Nature; 2018 Apr; 556(7701):293-295. PubMed ID: 29654293
    [No Abstract]   [Full Text] [Related]  

  • 45. Evolution of and perspectives on therapeutic approaches to nerve agent poisoning.
    Masson P
    Toxicol Lett; 2011 Sep; 206(1):5-13. PubMed ID: 21524695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progress in the development of enzyme-based nerve agent bioscavengers.
    Nachon F; Brazzolotto X; Trovaslet M; Masson P
    Chem Biol Interact; 2013 Dec; 206(3):536-44. PubMed ID: 23811386
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biological markers of exposure to organophosphorus nerve agents.
    Black RM; Read RW
    Arch Toxicol; 2013 Mar; 87(3):421-37. PubMed ID: 23371414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of haemostatic decontaminants for the treatment of wounds contaminated with chemical warfare agents. 1: evaluation of in vitro clotting efficacy in the presence of certain contaminants.
    Hall CA; Lydon HL; Dalton CH; Chipman JK; Graham JS; Chilcott RP
    J Appl Toxicol; 2015 May; 35(5):536-42. PubMed ID: 25131713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of next generation medical countermeasures to nerve agent poisoning.
    Wetherell J; Price M; Mumford H; Armstrong S; Scott L
    Toxicology; 2007 Apr; 233(1-3):120-7. PubMed ID: 16979808
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In search of a catalytic bioscavenger for the prophylaxis of nerve agent toxicity.
    diTargiani RC; Chandrasekaran L; Belinskaya T; Saxena A
    Chem Biol Interact; 2010 Sep; 187(1-3):349-54. PubMed ID: 20176006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A high-throughput UHPLC-MS/MS method for the quantification of five aged butyrylcholinesterase biomarkers from human exposure to organophosphorus nerve agents.
    Graham LA; Johnson D; Carter MD; Stout EG; Erol HA; Isenberg SL; Mathews TP; Thomas JD; Johnson RC
    Biomed Chromatogr; 2017 Apr; 31(4):. PubMed ID: 27572107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Small-scale purification of butyrylcholinesterase from human plasma and implementation of a μLC-UV/ESI MS/MS method to detect its organophosphorus adducts.
    John H; Breyer F; Schmidt C; Mizaikoff B; Worek F; Thiermann H
    Drug Test Anal; 2015 Oct; 7(10):947-56. PubMed ID: 25828536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treating exposure to chemical warfare agents: implications for health care providers and community emergency planning.
    Munro NB; Watson AP; Ambrose KR; Griffin GD
    Environ Health Perspect; 1990 Nov; 89():205-15. PubMed ID: 2088748
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of antidotes: problems and strategies.
    Szinicz L; Worek F; Thiermann H; Kehe K; Eckert S; Eyer P
    Toxicology; 2007 Apr; 233(1-3):23-30. PubMed ID: 16949190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Nerve gas--guidelines for care of victims of terrorism].
    Aas P; Jacobsen D
    Tidsskr Nor Laegeforen; 2005 Mar; 125(6):731-5. PubMed ID: 15776066
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of skin decontamination efficacy of commercial decontamination products following exposure to VX on human skin.
    Thors L; Koch M; Wigenstam E; Koch B; Hägglund L; Bucht A
    Chem Biol Interact; 2017 Aug; 273():82-89. PubMed ID: 28601555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Laboratory conditions and safety in a chemical warfare agent analysis and research laboratory.
    Kenar L; Karayilanoğlu T; Kose S
    Mil Med; 2002 Aug; 167(8):628-33. PubMed ID: 12188231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extraction of acidic degradation products of organophosphorus chemical warfare agents. Comparison between silica and mixed-mode strong anion-exchange cartridges.
    Kanaujia PK; Pardasani D; Gupta AK; Kumar R; Srivastava RK; Dubey DK
    J Chromatogr A; 2007 Aug; 1161(1-2):98-104. PubMed ID: 17570378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of the rePON1 mutant IIG1 to prevent cyclosarin toxicity in vivo and to detoxify structurally different nerve agents in vitro.
    Worek F; Seeger T; Goldsmith M; Ashani Y; Leader H; Sussman JS; Tawfik D; Thiermann H; Wille T
    Arch Toxicol; 2014 Jun; 88(6):1257-66. PubMed ID: 24477626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of selected skin decontaminant products and regimens against VX in domestic swine.
    Bjarnason S; Mikler J; Hill I; Tenn C; Garrett M; Caddy N; Sawyer TW
    Hum Exp Toxicol; 2008 Mar; 27(3):253-61. PubMed ID: 18650258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.